PMG
TTNP

ProVise Management Group’s Titan Pharmaceuticals TTNP Stock Holding History

ProVise Management Group’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8
Closed -$8K – 346
2016
Q3 		$8K Buy
+8
New +$155K ﹤0.01% 323

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ProVise Management Group's TTNP Position: Q4 2016 in Review

ProVise Management Group sold out of Titan Pharmaceuticals (TTNP) in Q4 2016, closing a stake of 8 shares — an estimated $8K sold.

ProVise Management Group first reported a position in TTNP in Q3 2016 and held it in 1 quarter. The position peaked at $8K in Q3 2016. 47 funds tracked by Wall St. Rank hold TTNP as of Q4 2016.

  • ProVise Management Group reported no remaining Titan Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • ProVise Management Group sold 8 Titan Pharmaceuticals shares in Q4 2016, an estimated $8K.
  • ProVise Management Group first reported a position in Titan Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • ProVise Management Group's Titan Pharmaceuticals position peaked at $8K in Q3 2016.
  • 47 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2016.

Based on ProVise Management Group's 13F filing for Q4 2016, filed 8 Feb 2017.